ChemotherapyFDA-approvedSecond-line
Cabazitaxel
How it works
Interferes with cell division, causing cancer cells to die.
Cancer types
Prostate Cancer— All patients
Efficacy
Cabazitaxel has been shown to improve survival and reduce disease progression in men with metastatic castration-resistant prostate cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Taxane Allergy: Unexpected Reaction to Cabazitaxel | Prostate Cancer | observational | — | Source → |
| Cabazitaxel Dosage May Affect Prostate Cancer Treatment Outcomes | Prostate Cancer | phase-3 | The OS effect of C25 increased with risk quartiles: -0.07 months (95% CI, -1.60 to 1.46) in the lowest risk quartile and 1.67 months (95% CI, 0.25 to 3.10) in the highest risk quartile. | Source → |
| New Nanoparticle Delivery System for Prostate Cancer Treatment | Prostate Cancer | animal-study | The high-dose CTX-NP group showed a tumor inhibition rate of 79.48%. | Source → |
| New Strategy to Combat Ovarian Cancer Resistance Identified | Ovarian Cancer | lab-study | — | Source → |
| Cabazitaxel Side Effect: Ureteritis in Prostate Cancer Patients | Prostate Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.